HCV / Hepatitis

The healthcare sector currently faces an unmet need in treating herpesviruses, hepatitis B, and hepatitis D, which could significantly improve patient outcomes. Addressing this involves considering the necessary steps and understanding the challenges pharmaceutical companies encounter as they work towards developing treatments for these conditions.

Colorado man infected with avian influenza, Novavax reveals promising results in JN1 covid vaccine efficacy, and recent roundups of c difficile news, and more from Contagion.

The test was validated as part of the NIH’s RADx tech program through its Independent Test Assessment Program, in collaboration with the FDA.

Findings from a pair of phase 2a trials showed combination imdusiran and IFN or VTP-300 with standard-of-care NA therapy led to meaningful and sustained reductions in HBsAg levels.

The study analyzed over 15 years shows declining rates of chronic and acute Hepatitis B in China, which is expected to make a significant contribution to the global elimination of hepatitis B by 2030.

Social determinants of health may determine hepatitis C management in the outpatient setting.

Zero HIV infections from the Phase 3 PURPOSE 1 Trial underscore the importance of innovative HIV prevention strategies across diverse populations.

Findings from the TAC ANRS 12311 trial revealed the success of tailored treatment combinations to the specific genotype of HCV to optimize efficacy and minimize adverse effects.

Overcoming “RSV identity crisis,” Moderna announced data for its investigational mRNA-1083 vaccine, BWC0977 effort to target drug-resistant pathogens, and more this week from Contagion.

Brii Biosciences presented new data from Phase 2 trials for chronic hepatitis B at EASL Congress 2024, revealing insights into the efficacy of BRII-179 as botha combined therapy and an additional treatment.

Innovative approach across opioid treatment programs bridges geographical barriers, achieving cure rates, and unlocking health benefits for underserved populations.

Atea pharmaceuticals is presenting data at a European liver conference this week showing a high efficacy for its combination therapy at 12 weeks post-treatment.

The clearance rate varied across states, but were not close to the 2025 or 2030 goals across all jurisdictions.

FDA approves Moderna's RSV vaccine for seniors, young women struggling with recurrent C difficile over the years, FDA grants Karius test to assist diagnosing infectious diseases, and more this week from Contagion.

A newer strategic approach combined with existing treatments are together trying to reduce incidence rates and cure people of HCV, but barriers to treatment remain, and often leave people outside the continuum of care.

This report underscores the increase of STIs alongside the ongoing global epidemics of HIV and viral hepatitis in the Americas and African regions.

Public health officials have confirmed 5 cases since mid-March with a separate case associated with a grocery store employee.

This week, irrigation water in Utah creates E coli outbreak, FDA issues CRL for HEPLISAV-B 4 dose regimen, living with C diff awareness, and more this week from Contagion.

Hepatitis awareness remains essential to promote prevention and early detection, ensuring access to vaccination and treatment, and improving public health.

Research indicates serum LOXL2 levels could serve as a predictor for hepatocellular carcinoma (HCC) risk in HCV patients who have achieved sustained virological response (SVR).

Dynavax is currently reviewing FDA feedback and strategizing a meeting to discuss their HEPLISAV-B 4-dose regimen for hemodialysis patients, determining the path forward toward approval.

Study examines the scarcity of data on the incidence of HBV-related hepatocellular carcinoma in West Africa.

On the day of a FDA PDUFA for a hepatitis B vaccine, it serves as reminder of great progress, but there remains a need to proliferate education especially around the liver.

Analysis reveals rising hospitalization rates among pregnant women with hepatitis C virus (HCV) and age as a critical factor influencing maternal and fetal health outcomes.

The modified difference-in-differences analysis found notable increases in DAA use after state Medicaid programs relaxed certain coverage restrictions.